TMEM147 is a novel biomarker for diagnosis and prognosis of hepatocellular carcinoma

Fan, Wei; Zhou, Mengxi; Wang, Didi; Jiang, Xinxin; Hao, Ding Jun

doi:10.1590/1678-4685-gmb-2022-0323

Cited by 6 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Changes in gene expression play a significant role in the pathogenesis of cancer [ 7 – 12 , 14 , 19 – 21 ]. For instance, the overexpression of transmembrane protein 147 (TMEM147) was observed in patients with hepatocellular carcinoma, and elevated TMEM147 expression was linked to poor prognosis [ 14 ]. Similarly, alterations in gene expression were implicated in the development of glioma [ 20 , 21 ].…”

Section: Discussionmentioning

confidence: 99%

SUMF1 overexpression promotes tumorous cell growth and migration and is correlated with the immune status of patients with glioma

Zhang,

Liu,

Wang

et al. 2024

Aging

View full text Add to dashboard Cite

Background: Glioma is a prevalent type of malignant tumor. To date, there is a lack of literature reports that have examined the association between sulfatase modifying factor 1 (SUMF1) and glioma. Methods: The levels of SUMF1 were examined, and their relationships with the diagnosis, prognosis, and immune microenvironment of patients with glioma were investigated. Cox and Lasso regression analysis were employed to construct nomograms and risk models associated with SUMF1. The functions and mechanisms of SUMF1 were explored and verified using gene ontology, cell counting kit-8, wound healing, western blotting, and transwell experiments. Results: SUMF1 expression tended to increase in glioma tissues. SUMF1 overexpression was linked to the diagnosis of cancer, survival events, isocitrate dehydrogenase status, age, and histological subtype and was positively correlated with poor prognosis in patients with glioma. SUMF1 overexpression was an independent risk factor for poor prognosis. SUMF1-related nomograms and high-risk scores could predict the outcome of patients with glioma. SUMF1 co-expressed genes were involved in cytokine, T-cell activation, and lymphocyte proliferation. Inhibiting the expression of SUMF1 could deter the proliferation, migration, and invasion of glioma cells through epithelial mesenchymal transition. SUMF1 overexpression was significantly associated with the stromal score, immune cells (such as macrophages, neutrophils, activated dendritic cells), estimate score, immune score, and the expression of the programmed cell death 1, cytotoxic T-lymphocyte associated protein 4, CD79A and other immune cell marker. Conclusion: SUMF1 overexpression was found to be correlated with adverse prognosis, cancer detection, and immune status in patients with glioma. Inhibiting the expression of SUMF1 was observed to deter the proliferation, migration, and invasion of cancer cells. The nomograms and risk models associated with SUMF1 could predict the prognosis of patients with glioma.

show abstract

Section: Discussionmentioning

confidence: 99%

SUMF1 overexpression promotes tumorous cell growth and migration and is correlated with the immune status of patients with glioma

Zhang,

Liu,

Wang

et al. 2024

Aging

View full text Add to dashboard Cite

show abstract

“…TMEM115 is a membrane protein; notably, membrane proteins constitute 30% of human proteins and have been used as a physiological and pathological biomarker [10,11]. Fan et al found that increased TMEM147 expression was associated with poor prognosis [14]. Furthermore, LIHC has demonstrated the potential of transmembrane protein as a biomarker.…”

Section: Discussionmentioning

confidence: 99%

“…Membrane proteins constitute 30% of the human proteins and are used as biomarkers in various physiological and pathological conditions [11]. In addition, Transmembrane proteins have been reported to novel biomarker for prognosis of LIHC [12][13][14]. However, the TMEM115, a transmembrane protein, has not been confirmed as a biomarker in LIHC; thus, its potential as a tumor biomarker must be confirmed.…”

Section: Introductionmentioning

confidence: 99%

Value of TMEM115 as a Potential Prognostic Biomarker in Liver Hepatocellular Carcinoma

Kim,

Kim

2023

Keimyung Med J

View full text Add to dashboard Cite

Transmembrane protein 115 (TMEM115) is a membrane protein; considering the potential of membrane proteins as biomarkers for various pathological conditions, we aimed to examine the value of TMEM115 as a potential biomarker for improving the prognosis and treatment of liver hepatocellular carcinoma (LIHC) in this study. Online databases including the Tumor Immune Estimation Resource, UALCAN, Gene Expression Profiling Interactive Analysis version 2, OSlihc, and human Protein Atlas were used. The analysis suggested that TMEM115 expression in LIHC was higher compared to normal tissues; further, TMEM115 expression was confirmed to be related with poor prognosis in LIHC. Higher protein expression levels of TMEM115 were observed in LIHC tissues than in normal tissues. Tumor infiltration by immune cells was confirmed to be correlated with the expression of TMEM115. High TMEM115 expression and immune cell infiltration were further related to poor prognosis in LIHC. We also confirmed a correlation between TMEM115 and TP53 mutations. In conclusion, we confirmed that TMEM115 expression is correlated with tumor-infiltrating immune cells and poor prognosis in LIHC and that TMEM115 shows potential as a prognostic biomarker in LIHC.

show abstract

Transcription factors ASCL1 and OLIG2 drive glioblastoma initiation and co-regulate tumor cell types and migration

Myers,

Brayer,

Paez-Beltran

et al. 2024

Nat Commun

View full text Add to dashboard Cite

Glioblastomas (GBMs) are highly aggressive, infiltrative, and heterogeneous brain tumors driven by complex genetic alterations. The basic-helix-loop-helix (bHLH) transcription factors ASCL1 and OLIG2 are dynamically co-expressed in GBMs; however, their combinatorial roles in regulating the plasticity and heterogeneity of GBM cells are unclear. Here, we show that induction of somatic mutations in subventricular zone (SVZ) progenitor cells leads to the dysregulation of ASCL1 and OLIG2, which then function redundantly and are required for brain tumor formation in a mouse model of GBM. Subsequently, the binding of ASCL1 and OLIG2 to each other’s loci and to downstream target genes then determines the cell types and degree of migration of tumor cells. Single-cell RNA sequencing (scRNA-seq) reveals that a high level of ASCL1 is key in specifying highly migratory neural stem cell (NSC)/astrocyte-like tumor cell types, which are marked by upregulation of ribosomal protein, oxidative phosphorylation, cancer metastasis, and therapeutic resistance genes.

show abstract

TMEM147 is a novel biomarker for diagnosis and prognosis of hepatocellular carcinoma

Cited by 6 publications

References 31 publications

SUMF1 overexpression promotes tumorous cell growth and migration and is correlated with the immune status of patients with glioma

SUMF1 overexpression promotes tumorous cell growth and migration and is correlated with the immune status of patients with glioma

Value of TMEM115 as a Potential Prognostic Biomarker in Liver Hepatocellular Carcinoma

Transcription factors ASCL1 and OLIG2 drive glioblastoma initiation and co-regulate tumor cell types and migration

Contact Info

Product

Resources

About